‘Global Overactive Bladder Treatment Market Set To Grow To $4.0bn By 2023’ says latest research by Visiongain

27 July 2018
Pharma

Visiongain’ has launched a new pharma report Global Overactive Bladder Treatment Market 2018-2028: Prescription Drugs, OTC Drugs, Short-term Therapy, Long-term Therapy
It is estimated that about one in six adults in the US and Europe have over active bladder syndrome. The prevalence rate of over active bladder increases with age and thus it is expected that over active bladder will become more common in the future as the average age of people living in the developed countries is significantly increasing. The Global Overactive bladder therapeutic market is growing rapidly, with large opportunity to grow in the untapped APAC region mainly because of the introduction of low-cost generic products in rapidly developing countries such as India and China.
The lead analyst of the report commented “The global overactive bladder therapeutic market is driven by several factors such as increasing prevalence of urinary incontinence, increasing awareness of the disease and its comorbidities, growing diagnosis and treatment rates as well as limited number of current players. Moreover, there are various national and international level policies being adopted by a growing number of countries to combat overactive bladder related symptoms”

Leading companies featured in the report include Allergan, Apotex, Astellas, Medtronic, Mylan, Pfizer, Sanofi.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes NGS-Based RNA Sequencing Market Report 2021-2031

The market is expected to be driven by key factors such as rising cancer prevalence, government funding support in genetic research and technological advancements taking place in the biological research field. In addition, the market is predicted to gain huge traction in the developing countries.

11 May 2021

Read

Visiongain Publishes Single-Use Bioreactors Market Report 2021-2031

Strong product portfolio in the market is one of the major factors accelerating the growth of the market as availability of variants in the single-use systems allows targeted users more options.

11 May 2021

Read

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021

Read

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever